1
|
Henriksson C, Olsson A, Andersen K, Arefalk G, Erlinge D, Hofmann R, Ridderstråle W, Rutgersson A, Oldgren J, James S. Patients' experiences of clinical trial participation involving a product remotely assessing study drug adherence. Contemp Clin Trials Commun 2024; 40:101307. [PMID: 38947982 PMCID: PMC11214196 DOI: 10.1016/j.conctc.2024.101307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2023] [Revised: 04/23/2024] [Accepted: 05/12/2024] [Indexed: 07/02/2024] Open
Abstract
Background The participation of patients in clinical trials is crucial for the development of healthcare. There are several challenges in the recruitment of trial participants with acute medical conditions. The registry-based randomized DAPA-MI clinical trial recruited patients during hospitalization for myocardial infarction and provided study drugs in bottles with smart caps that used wireless technology to transmit monitoring data. This interview study aimed to investigate patients' experience of participation in a clinical trial and their attitude to the new bottle cap technology. Methods A subset of patients participating in the DAPA-MI trial were recruited from four hospitals in Sweden. Semi-structured interviews were conducted and analysed using manifest content analysis. Results Video interviews were performed including 21 patients (four women and 17 men). The median age was 59 years (range 44-80). Four categories of patients' experiences were identified. A willingness to contribute consisted of patients' positive attitudes to participation and to be a part of development and research. The perception of information emphasized the value of the oral information as well as the importance of time for reflection. Be in a vulnerable condition highlighted the impaired ability to perceive and remember in the acute medical condition. Adaptation to a new technology described the overall positive experiences of the smart bottle cap to evaluate adherence. Conclusions Patients' experiences of trial participation were in general positive but some challenges in the acute setting of a myocardial infarction were revealed. The smart bottle cap was well accepted, despite some handling difficulties.
Collapse
Affiliation(s)
- Catrin Henriksson
- Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
| | - Anneli Olsson
- Cardiology, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - Kasper Andersen
- Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
| | - Gabriel Arefalk
- Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
- Thoracic Centre, Blekinge Hospital, Karlskrona, Sweden
| | - David Erlinge
- Cardiology, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - Robin Hofmann
- Division of Cardiology, Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden
| | - Wilhelm Ridderstråle
- Late-Stage Development, Cardiovascular, Renal and Metabolic, Biopharmaceuticals Research & Development, AstraZeneca, Gothenburg, Sweden
| | - Annika Rutgersson
- Digital Health, Biopharmaceuticals Research & Development, AstraZeneca, Gothenburg, Sweden
| | - Jonas Oldgren
- Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
- Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
| | - Stefan James
- Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
- Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
| |
Collapse
|
2
|
Boyd P, Sternke EA, Tite DJ, Morgan K. "There was No Opportunity to Express Good or Bad": Perspectives From Patient Focus Groups on Patient Experience in Clinical Trials. J Patient Exp 2024; 11:23743735241237684. [PMID: 38487673 PMCID: PMC10938610 DOI: 10.1177/23743735241237684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/17/2024] Open
Abstract
To understand how patients perceive their experiences leading up to, during, and after a clinical trial, and the relationship these experiences had with future willingness to participate, we conducted 3 focus groups with patients who had prior clinical trial involvement (n = 25). Discussion topics included clinical trial discovery, enrollment, communication, trust, patient-centricity, and future enrollment. Patient focus groups revealed a variety of motivations for enrolling in clinical trials (eg, altruism, efficacious treatment, curiosity, desperation, etc.). Patients learned about clinical trials through trusted sources (eg, primary care physicians, patient advocacy groups) and social media. Access and uncertainty about clinical trials were barriers to enrollment. Patient-centric communication and attention given to disease states and symptom severity were valued and made patients feel genuinely cared about. Post-trial follow up and being informed of trial results were inconsistently reported by patients. Critically, patients described frustration with an overall lack of patient experience measurement. Patients identified a need to measure experiences before, during, and after clinical trials and emphasized that doing so would facilitate patient trust and overall experience.
Collapse
Affiliation(s)
- Patrick Boyd
- Press Ganey Associates, LLC, South Bend, IN, USA
- *Current affiliation: Department of Population Sciences, City of Hope, Duarte, CA, USA
| | | | - David J Tite
- Press Ganey Associates, LLC, South Bend, IN, USA
| | | |
Collapse
|
3
|
Kost RG, Cheng A, Andrews J, Chatterjee R, Dozier A, Ford D, Schlesinger N, Dykes C, Kelly-Pumarol I, Kennedy N, Lewis-Land C, Lindo S, Martinez L, Musty M, Roberts J, Vaughan R, Wagenknecht L, Carey S, Coffran C, Goodrich J, Panjala P, Cheema S, Qureshi A, Thomas E, O’Neill L, Bascompte-Moragas E, Harris P. Empowering the Participant Voice (EPV): Design and implementation of collaborative infrastructure to collect research participant experience feedback at scale. J Clin Transl Sci 2024; 8:e40. [PMID: 38476242 PMCID: PMC10928700 DOI: 10.1017/cts.2024.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 01/15/2024] [Accepted: 01/25/2024] [Indexed: 03/14/2024] Open
Abstract
Empowering the Participant Voice (EPV) is an NCATS-funded six-CTSA collaboration to develop, demonstrate, and disseminate a low-cost infrastructure for collecting timely feedback from research participants, fostering trust, and providing data for improving clinical translational research. EPV leverages the validated Research Participant Perception Survey (RPPS) and the popular REDCap electronic data-capture platform. This report describes the development of infrastructure designed to overcome identified institutional barriers to routinely collecting participant feedback using RPPS and demonstration use cases. Sites engaged local stakeholders iteratively, incorporating feedback about anticipated value and potential concerns into project design. The team defined common standards and operations, developed software, and produced a detailed planning and implementation Guide. By May 2023, 2,575 participants diverse in age, race, ethnicity, and sex had responded to approximately 13,850 survey invitations (18.6%); 29% of responses included free-text comments. EPV infrastructure enabled sites to routinely access local and multi-site research participant experience data on an interactive analytics dashboard. The EPV learning collaborative continues to test initiatives to improve survey reach and optimize infrastructure and process. Broad uptake of EPV will expand the evidence base, enable hypothesis generation, and drive research-on-research locally and nationally to enhance the clinical research enterprise.
Collapse
Affiliation(s)
- Rhonda G. Kost
- The Rockefeller University Center for Clinical and Translational
Science, New York, NY, USA
| | - Alex Cheng
- Department of Biomedical Informatics, Vanderbilt
University, Nashville, TN,
USA
| | - Joseph Andrews
- Wake Forest School of Medicine, Clinical and Translational
Science Institute, Winston-Salem, NC,
USA
| | - Ranee Chatterjee
- Department of Medicine, Duke University School of
Medicine, Duke Clinical Translational Science Institute,
Durham, NC, USA
| | - Ann Dozier
- Department of Public Health Sciences, School of Medicine and Dentistry,
University of Rochester, Rochester,
NY, USA
| | - Daniel Ford
- Johns Hopkins University Institute for Clinical and Translational
Research, Baltimore, MD, USA
| | - Natalie Schlesinger
- The Rockefeller University Center for Clinical and Translational
Science, New York, NY, USA
| | - Carrie Dykes
- Clinical and Translational Science Institute, University of
Rochester, Rochester, NY, USA
| | - Issis Kelly-Pumarol
- Wake Forest School of Medicine, Clinical and Translational
Science Institute, Winston-Salem, NC,
USA
| | - Nan Kennedy
- Vanderbilt Institute for Clinical and Translational Research,
Vanderbilt University Medical Center, Nashville,
TN, USA
| | - Cassie Lewis-Land
- Johns Hopkins University Institute for Clinical and Translational
Research, Baltimore, MD, USA
| | - Sierra Lindo
- Duke Clinical Translational Science Institute,
Durham, NC, USA
| | - Liz Martinez
- Johns Hopkins University Institute for Clinical and Translational
Research, Baltimore, MD, USA
| | - Michael Musty
- Duke Clinical Translational Science Institute,
Durham, NC, USA
| | | | - Roger Vaughan
- The Rockefeller University Center for Clinical and Translational
Science, New York, NY, USA
| | - Lynne Wagenknecht
- Wake Forest School of Medicine, Clinical and Translational
Science Institute, Winston-Salem, NC,
USA
| | - Scott Carey
- Johns Hopkins University Institute for Clinical and Translational
Research, Baltimore, MD, USA
| | - Cameron Coffran
- The Rockefeller University Center for Clinical and Translational
Science, New York, NY, USA
| | - James Goodrich
- Duke University School of Medicine, Duke Office of Clinical
Research, Durham, NC, USA
| | - Pavithra Panjala
- Clinical and Translational Science Institute, University of
Rochester, Rochester, NY, USA
| | - Sameer Cheema
- Duke University School of Medicine, Duke Office of Clinical
Research, Durham, NC, USA
| | - Adam Qureshi
- The Rockefeller University Center for Clinical and Translational
Science, New York, NY, USA
| | - Ellis Thomas
- Department of Biomedical Informatics, Vanderbilt
University, Nashville, TN,
USA
| | - Lindsay O’Neill
- Department of Biomedical Informatics, Vanderbilt
University, Nashville, TN,
USA
| | | | - Paul Harris
- Department of Biomedical Informatics, Vanderbilt
University, Nashville, TN,
USA
| |
Collapse
|
4
|
Victoria-Castro AM, Corona-Villalobos CP, Xu AY, Onul I, Huynh C, Chen SW, Ugwuowo U, Sarkisova N, Dighe AL, Blank KN, Blanc VM, Rose MP, Himmelfarb J, de Boer IH, Tuttle KR, Roberts GV. Participant Experience with Protocol Research Kidney Biopsies in the Kidney Precision Medicine Project. Clin J Am Soc Nephrol 2024; 19:202-212. [PMID: 37871973 PMCID: PMC10861112 DOI: 10.2215/cjn.0000000000000334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 10/16/2023] [Indexed: 10/25/2023]
Abstract
BACKGROUND Kidney biopsies are procedures commonly performed in clinical nephrology and are increasingly used in research. In this study, we aimed to evaluate the experiences of participants who underwent research kidney biopsies in the Kidney Precision Medicine Project (KPMP). METHODS KPMP research participants with AKI or CKD were enrolled at nine recruitment sites in the United States between September 2019 and January 2023. At 28 days postbiopsy, participants were invited to complete a survey to share their experiences, including motivation to participate in research, comprehension of informed consent, pain and anxiety during and after the biopsy procedure, overall satisfaction with KPMP participation, and effect of the study on their lives. The survey was developed in collaboration with the KPMP Community Engagement Committee and the Institute of Translational Health Sciences at the University of Washington. RESULTS One hundred and eleven participants completed the survey, 23 enrolled for AKI and 88 for CKD. The median age was 61 (interquartile range [IQR], 48-67) years, 43% were women, 28% were Black, and 18% were of Hispanic ethnicity. Survey respondents most commonly joined KPMP to help future patients (59%). The consent form was understood by 99%, and 97% recognized their important role in this study. Pain during the biopsy was reported by 50%, at a median level of 1 (IQR, 0-3) on a 0-10 scale. Anxiety during the biopsy was described by 64% at a median level of 3 (IQR, 1-5) on a 0-10 scale. More than half conveyed that KPMP participation had an effect on their diet, physical activity, and how they think about kidney disease. CONCLUSIONS KPMP survey respondents were most commonly motivated to participate in research protocol kidney biopsies by altruism, with excellent understanding of the informed consent process. PODCAST This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_20_CJN0000000000000334.mp3This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_20_Spanish_CJN00000000.mp3.
Collapse
Grants
- R01 DK121019 NIDDK NIH HHS
- U01 DK114866 NIDDK NIH HHS
- U01 DK133090 NIDDK NIH HHS
- U01 DK114933 NIDDK NIH HHS
- U01 DK114908 NIDDK NIH HHS
- U01 DK133095 NIDDK NIH HHS
- U01 DK133081 NIDDK NIH HHS
- U01 DK114907 NIDDK NIH HHS
- U01 DK114920 NIDDK NIH HHS
- U24 DK114886 NIDDK NIH HHS
- U01 DK133766 NIDDK NIH HHS
- U01 DK114923 NIDDK NIH HHS
- U01 DK133113 NIDDK NIH HHS
- U01 DK133097 NIDDK NIH HHS
- U01DK133081, U01DK133091, U01DK133092, U01DK133093, U01DK133095, U01DK133097, U01DK114866, U01DK114908, U01DK133090, U01DK133113, U01DK133766, U01DK133768, U01DK114907, U01DK114920, U01DK114923, U01DK114933, U24DK114886. NIDDK NIH HHS
- U01 DK133768 NIDDK NIH HHS
- U01 DK133092 NIDDK NIH HHS
- U01 DK133091 NIDDK NIH HHS
- U01 DK133093 NIDDK NIH HHS
Collapse
Affiliation(s)
| | | | - Alan Y. Xu
- Division of Nephrology, School of Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Ingrid Onul
- Boston Medical Center, Boston, Massachusetts
| | | | - Sarah W. Chen
- Kidney and Hypertension Unit, Joslin Diabetes Center, Boston, Massachusetts
| | - Ugochukwu Ugwuowo
- Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, Connecticut
| | - Natalya Sarkisova
- Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington
| | - Ashveena L. Dighe
- Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington
| | - Kristina N. Blank
- Department of Biostatistics, University of Washington, Seattle, Washington
| | - Victoria M. Blanc
- Office of Research, University of Michigan Medical School, Ann Arbor, Michigan
| | - Michael P. Rose
- Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington
| | - Jonathan Himmelfarb
- Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington
| | - Ian H. de Boer
- Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington
| | - Katherine R. Tuttle
- Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington
| | - Glenda V. Roberts
- Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington
- Kidney Precision Medicine Project Patient Partner, Seattle, Washington
| |
Collapse
|
5
|
Goodson N, Wicks P, Farina C. Commentary: an industry perspective on the importance of incorporating participant voice before, during, and after clinical trials. Trials 2022; 23:966. [DOI: 10.1186/s13063-022-06905-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 11/08/2022] [Indexed: 11/29/2022] Open
Abstract
AbstractIt is increasingly recognized that involving patients and the public in the design of clinical trials can lead to better recruitment, retention, and satisfaction. A recent scoping review determined that between 1985 and 2018, just 23 articles meeting quality criteria obtained feedback from clinical trial participants after a trial had been completed. In a timespan that presumably included thousands of trials across hundreds of indications, the paucity of the literature seems surprising, if not outright disappointing. By contrast, practitioners in the life sciences industry are increasingly incorporating patient research into their trial design process before, during, and after trial completion. Examples of approaches used include recruitment of “look alike” participant samples through online communities, surveys, and the use of smartphone apps to directly record participants’ spoken reactions to trial materials like recruitment materials, site visit schedules, or informed consent materials. However, commercial organizations tend not to publish their findings, leading to a potential two-tier experience for trial participants depending on whether the trial they participate in will be industry-funded or government-funded. This seems problematic on a number of levels. Increasing regulatory, funder, and publisher interest in improving the inclusivity of clinical trial participants may act as a timely lever to spur patient-centered coproduction of trials. Until continuous feedback processes are the mandated, funded, and published norm, participating in a clinical trial will be more arduous than it needs to be.
Collapse
|